文献速递卫生政策与健康促进免疫规划

超越成本效益:利用系统分析进行传染病防范

Beyond cost-effectiveness: Using systems analysis for infectious disease preparedness.
PubMed 文献 · Vaccine · 2016-12-22

基于成本效益分析,埃博拉疫苗在决策者优先级列表中排名较低。尽管埃博拉相关病例和死亡人数相对较少,埃博拉疫苗却突然跃升至国际卫生机构和疫苗开发商的最高优先级。多标准系统分析可以改进疫苗开发和其他卫生政策与投资决策的评估与优先级排序。

要点

  • 成本效益分析可能遗漏影响现实决策的因素,如不平等和差异。
  • 多标准系统分析能更有效地指导决策和改变优先级设定过程。
  • 使用SMART Vaccines展示系统分析如何纳入重要的「其他因素」。

核心结论

  • 多标准系统分析可以改进疫苗开发和其他卫生政策与投资决策的评估与优先级排序。
  • 使用SMART Vaccines展示系统分析能 visibly 纳入重要的「其他因素」,更有效地指导决策并有益地改变优先级设定过程。

研究设计与样本

  • 原文未报告研究设计与样本。

主要发现

  • 基于成本效益分析,埃博拉疫苗在决策者优先级列表中排名较低。
  • 尽管埃博拉相关病例和死亡人数相对较少,埃博拉疫苗却突然跃升至国际卫生机构和疫苗开发商的最高优先级。
  • 成本效益和成本效益分析都无法捕捉埃博拉或寨卡等问题的关键方面,特别是不平等和差异问题。
  • 成本效益分析需要对生命的具体价值做出假设,这令许多分析师和决策者反感。
  • 标准成本效益计算通常无法捕捉对未感染埃博拉但通过传染、群体免疫、恐惧、旅行和商业减少以及疾病根除希望等因素受影响的人群的影响。

关键数值与推荐

  • 原文未报告关键数值与推荐。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Until the recent outbreaks, Ebola vaccines ranked low in decision makers' priority lists based on cost-effectiveness analysis and (or) corporate profitability. Despite a relatively small number of Ebola-related cases and deaths (compared to other causes), Ebola vaccines suddenly leapt to highest priority among international health agencies and vaccine developers. Clearly, earlier cost-effectiveness analyses badly missed some factors affecting real world decisions. Multi-criteria systems analysis can improve evaluation and prioritization of vaccine development and also of many other health policy and investment decisions. Neither cost-effectiveness nor cost-benefit analysis can capture important aspects of problems such as Ebola or the emerging threat of Zika, especially issues of inequality and disparity-issues that dominate the planning of many global health and economic organizations. Cost-benefit analysis requires assumptions about the specific value of life-an idea objectionable to many analysts and policy makers. Additionally, standard cost-effectiveness calculations cannot generally capture effects on people uninfected with Ebola for example, but nevertheless affected through such factors as contagion, herd immunity, and fear of dread disease, reduction of travel and commerce, and even the hope of disease eradication. Using SMART Vaccines, we demonstrate how systems analysis can visibly include important "other factors" and more usefully guide decision making and beneficially alter priority setting processes.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Phelps C, Madhavan G, Rappuoli R, et al. Beyond cost-effectiveness: Using systems analysis for infectious disease preparedness. Vaccine. 2016. PMID: 28017432. doi:10.1016/j.vaccine.2016.08.090

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。